Skip to content

Kura Oncology, Inc.

KURA· NasdaqCore metricsCIK 1422143

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -3.88%
Market cap
$682.66M
91.88M shares
Filings
816
$22.84M
Q3 2026+25.2% FY25 yoy
-$70.22M
Q3 2026N/M FY25 yoy
-$74.66M
Q3 2026N/M FY25 yoy
-$204.08M
Q3 2026derivedN/M FY25 yoy
-$0.78
Q3 2026N/M FY25 yoy
$57.94M
Q3 2026−33.6% FY25 yoy
$682.66M
—
8.6×
38.0×
-13.06%
—

Twelve months to Sep 30, 2026 · derived

Price

$7.4330.63%$3.28past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$67.48MFY 2025
$67.48M0FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$67,482,000reported
FY 20242024-12-31$53,883,000reported
FY 20232023-12-31$0reported

Segments

Products
Revenue by Products, FY2023 to FY2025FY2023FY2024Collaboration Revenue · FY2024 · $53.88MCollaboration revenue · FY2024 · $53.88MFY2025Collaboration Revenue · FY2025 · $65.35MCollaboration revenue · FY2025 · $65.35MProduct revenue, net · FY2025 · $2.13M
LineFY2025ShareChange
Collaboration Revenue$65.35M97%+21.3%
Collaboration revenue$65.35M97%+21.3%
Product revenue, net$2.13M3.2%—
Total$67.48M

From the 10-K filed Mar 5, 2026KURA

Pharmaceutical preparations

Kura Oncology, Inc. is the 117th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Kura Oncology, Inc. · CIK 1422143 · Engraved from SEC EDGAR